Cryo-Cell International, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)				1 Months Ended	12 Months Ended
	Apr. 15, 2024 USD ($)	Jun. 01, 2017 USD ($)	Feb. 01, 2012 USD ($)	Dec. 31, 2005 USD ($)	Nov. 30, 2025 USD ($) Unit Segment shares	Nov. 30, 2024 USD ($) shares
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Number of reportable segments \| Segment					3
Concentration risk related to supplier					The Company depends on one supplier for the source of its collection kits
Deferred revenue					$ 60,704,996
Warranty payment		$ 100,000	$ 75,000	$ 50,000
Commission paid					33,301	$ 45,375
Additional capitalized contract acquisition costs, net of amortization expense					124,099	118,498
Impairment of contract assets					0	0
Uncertain tax provisions					0	0
Provisions for interest or penalties related to uncertain tax positions					0	0
Advertising cost included in selling, general and administrative expenses					1,087,570	1,067,392
Unrealized holding (losses) gains, marketable securities					(806,267)	1,076,051
Gain on interest rate swap	$ 228,000				$ 0	105,887
Payment warranty				$ 50,000
Increased payment warranty		$ 100,000	$ 75,000
Number of outstanding options excluded from computation of diluted earnings per share \| shares					1,029,978
Stock-based option compensation expense					$ 417,000	$ 781,000
Employee Stock Option
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Number of outstanding options excluded from computation of diluted earnings per share \| shares						639,745
Other Nonoperating Income (Expense) [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Unrealized holding (losses) gains, marketable securities					$ 806,267	$ 1,076,051
Duke University [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contracted storage amortization period					16 years
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] \| Duke University [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Inventory, in units \| Unit					6,000
Number of units, per month \| Unit					36
Maximum [Member] \| Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] \| Duke University [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Inventory, in units \| Unit					36
Accounts Receivables [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Period of doubtful for accounts receivable due from client					30 days
Option One [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contracted storage amortization period					1 year
Option Two [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contracted storage amortization period					18 years
Option Three [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contracted storage amortization period					21 years
Option Four [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contracted storage amortization period					lifetime
Contracted storage amortization description					The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue.
Tianhe Stem Cell Biotechnologies Inc [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Impairment of investment					$ 0	$ 308,000